Direxion Daily LLY Bull 2X ETF (ELIL)

ELIL is a leveraged exchange-traded fund designed to amplify daily moves in Eli Lilly stock. If Eli Lilly rises 1 percent on a given day, ELIL aims to rise 2 percent. If LLY falls 1 percent, ELIL falls 2 percent. The amplification is achieved through borrowing and derivatives that create a 2x leveraged position in the underlying stock. At the end of each trading day, Direxion (the fund’s sponsor) rebalances back to the target 2x ratio so that the next day’s leverage is reset.

This daily rebalancing creates a fundamental consequence that most retail investors overlook: over longer holding periods, ELIL tends to underperform twice the stock’s cumulative return. Suppose Eli Lilly stock rises 10 percent on day one and falls 9 percent on day two. The stock is up roughly 0.1 percent net. ELIL would rise 20 percent on day one, then fall 18 percent on day two, ending up around 0.4 percent. But in choppy, sideways markets—where the stock oscillates up and down multiple times—the daily rebalancing friction gradually erodes returns. This decay accelerates with volatility. The fund must buy high and sell low as it rebalances each day to maintain the 2x leverage, and over time those forced trades drain value. This is not a bug but an unavoidable cost of the instrument’s design.

The intended use case is short-term tactical trading. An investor who expects Eli Lilly to rally and wants double-amplified exposure for a few days or weeks can use ELIL to leverage that conviction without borrowing on margin from a broker. But the fund is catastrophic for buy-and-hold investors. If you believe Eli Lilly will double over five years, owning the stock itself will deliver far better results than holding ELIL, even accounting for the stock’s gains. The leverage is a day-trading amplifier, not a wealth creator over time.

The cost structure reflects the leverage. ELIL’s expense ratio is around 0.95 percent annually—significantly higher than owning the stock outright—because leverage costs money to maintain. Bid-ask spreads are also wider than for a typical stock ETF, adding friction for traders. The fund tracks the closing price of Eli Lilly, not intraday moves, which creates a gap between what traders see during the day and where the fund actually positions itself.

The downside risk is severe. If Eli Lilly falls 50 percent, ELIL falls roughly 100 percent, wiping out the entire investment. The daily rebalancing cannot protect against sharp drops; if anything, it forces the fund to sell into declines, realizing losses at the worst moments. Dividends also hurt ELIL. When Eli Lilly pays a dividend, the stock gaps down by the dividend amount on the ex-date. ELIL gaps down twice as much, and the daily rebalancing does not recover that loss. Over time, dividends drag returns for leveraged investors more than they do for unleveraged stock holders.

ELIL is strictly for experienced traders with a specific short-term directional view and a clear exit plan. It is unsuitable for retirement accounts, for building long-term wealth, or for investors uncomfortable with losing money fast. Anyone considering this fund should read the prospectus carefully, understand the daily rebalancing mechanics and volatility decay, and have a real reason to believe Eli Lilly will move sharply in the near term. If the rationale is “I am bullish for the long haul,” owning the stock is cheaper, simpler, and far more likely to succeed.